See adverse reactions attributed to class:

Antineoplastic / anticancer agent

Biologic

Tyrosine kinase inhibitor

Acneiform eruption / acneiform dermatitis / acneiform rash 

(2018): Hwang A+, J Oncol Pharm Pract Jan, Epub ahead of print

(2011): Demirci U+, J Oncol Pharm Pract 17(3), 285

(2006): Martin JM+, J Eur Acad Dermatol Venereol 20(10), 1368

Acute febrile neutrophilic dermatosis (Sweet's syndrome) 

(2018): Biswal SG+, Indian J Dermatol 63(1), 41

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2005): Ayirookuzhi SJ+, Arch Dermatol 141(3), 368

Acute generalized exanthematous pustulosis (AGEP) 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2015): Scott AD+, Clin Exp Dermatol 40(8), 926

(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655

(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2002): Schwarz M+, Eur J Haematol 69(4), 254 (2 cases)

(2001): Brouard MC+, Dermatology 203(1), 57

Carcinoma 

(2005): Breccia M+, Eur J Haematol 74(2), 121

Dermatomyositis 

(2006): Kuwano Y+, Int J Dermatol 45(10), 1249

Diaphoresis 13%

(package insert)

DRESS syndrome 

(2019): Zgolli F+, Curr Drug Saf Jan, Epub ahead of print1 case (grade 3+)

(2017): Vatel O+, Leuk Lymphoma 58(2), 473

(2008): Goldman J+, Ann Dermatol Venereol 135 (5), 393

(2006): Le Nouail P+, Ann Dermatol Venereol 133(8-9 Pt 1), 686

Edema / fluid retention (see also peripheral edema) <5%

(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print62% (3% grade 3/4)

(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print13%

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11317%Pediatric

(2018): Fu Y+, Thorac Cancer Mar, Epub ahead of print39%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16062%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]40–74%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]60%

(2016): Dervis E+, Eur J Dermatol 26(2), 133

(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55451%

(2015): Brummendorf TH+, Br J Haematol 168(1), 69

(2014): Hsu CC+, Anticancer Res 34(9), 5029

(2014): Linga VG+, South Asian J Cancer 3(4), 20339%Pediatric

(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655

(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]

(2014): Thota NK+, Indian J Cancer 51(1), 580%

(2013): Matti BF+, Turk J Haematol 30(4), 38752%

(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34(2), 93

(2012): Cortes JE+, J Clin Oncol 30(28), 3486

(2012): Kantarjian HM+, Blood 119(5), 1123

(2012): Radich JP+, Blood 120(19), 389850%

(2011): Imagawa J+, Rinsho Ketsueki 52(7), 546

(2011): Khanna D+, Arthritis Rheum 63(11), 3540 (lower extremity)

(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Modi S+, Breast Cancer Res 90(2), 15738%

(2005): Severino G+, Ann Pharmacother 39(1), 162

(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]

(2003): Prescrire Int 12(64), 49<5%

(2003): Shimazaki C+, Leukemia 17(4), 804

(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (35 cases)

(2002): Dagher R+, Clin Cancer Res 8(10), 3034

(2002): Demetri GD+, N Engl J Med 347(7), 472

(2002): Pindolia VK+, Pharmacotherapy 22(10), 1249 [REVIEW]

(2002): Tefferi A+, Blood 99(10), 3854

(2001): van Oosterom AT+, Lancet 358(9291), 1421

Erythema <10%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Sugito M+, Rinsho Ketsueki 46(11), 1226

(2003): Duncan E+, Br J Haematol 122(1), 1

(2003): Pasmatzi E+, Acta Derm Venereol 83(5), 391

Erythema multiforme 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

Erythema nodosum 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

Erythroderma 

(2018): Lunge S+, J Assoc Physicians India 66(12), 79 (1 case)

(2013): Verma R+, Indian J Pharmacol 45(6), 634

(2007): Vano-Galvan S+, Eur J Dermatol 17(6), 538

(2006): Oztas P+, Acta Derm Venereol 86(2), 174

Exanthems 

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2010): Hwang JE+, BMC Cancer 10, 438

(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2004): Park MA+, Allergy Asthma Proc 25(5), 345 [REVIEW]

(2003): Dogra S+, Natl Med J India 16(5), 285

(2002): Dagher R+, Clin Cancer Res 8(10), 3034

Exfoliative dermatitis 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2010): Hwang JE+, BMC Cancer 10, 438

(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216

(2003): Tanvetyanon T+, Ann Pharmacother 37(12), 1818

Facial edema <10%

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2014): Thota NK+, Indian J Cancer 51(1), 5

(2011): Khanna D+, Arthritis Rheum 63(11), 3540

Folliculitis 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

Graft-versus-host reaction 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

Hand–foot syndrome (palmar–plantar erythrodysesthesia) 

(2012): Kumar P+, J Postgrad Med 58(4), 331

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

(2008): Battistella M+, Arch Dermatol 144(10), 1400

Hyperhidrosis 

(2016): Dervis E+, Eur J Dermatol 26(2), 133

Hypomelanosis 

(2013): Sibaud V+, Ann Dermatol Venereol 140(4), 266

(2006): Brazzelli V+, Pediatr Dermatol 23(2), 175

(2005): McPartlin S+, Br J Haematol 129(4), 448

(2004): Grossman WJ+, J Pediatr Hematol Oncol 26(3), 214

(2003): Tsao AS+, Cancer 98(11), 2483

Keratoses 

(2017): Benabbes M+, Ann Pharm Fr 75(3), 172

Lesions 

(2016): Paolino G+, Cutis 97(6), e12

Leukocytoclastic vasculitis (angiitis) 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

Lichen planus 

(2011): Sudha R+, Indian J Dermatol 56(3), 351

(2009): Kaliyadan F+, Indian J Dermatol Venereol Leprol 75(5), 527

(2009): Martinez de Lagran Z+, Med Clin (Barc) 133(20), 805

(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14

(2004): Roux C+, Ann Dermatol Venereol 131(6-7 Pt I), 571

Lichenoid eruption 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW]

(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2014): De D+, Indian J Dermatol Venereol Leprol 80(1), 93

(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655

(2013): Ghosh SK, Indian J Dermatol 58(5), 388 [REVIEW]

(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14

(2007): Chan CY+, Dermatol Online J 13(2), 29

(2006): Dalmau J+, Br J Dermatol 154(6), 1213

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Prabhash K+, Indian J Derm, Venereol Leprol 71(4), 287

(2002): Lim DS+, Dermatology 205(2), 169-71 (1 case / female)

Maculopapular rash / morbilliform rash  

(2018): Lunge S+, J Assoc Physicians India 66(12), 79 (1 case)

Melasma 

(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 [REVIEW] (5 cases)

Mycosis fungoides 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

Necrolysis 

(2003): Schaich M+, Ann Hematol 82(5), 303

Neutrophilic eccrine hidradenitis 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Dib EG+, Leuk Res 29(2), 233

Panniculitis 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2011): de Masson A+, Ann Dermatol Venereol 138(2), 135Geriatric

(2003): Ugurel S+, Br J Dermatol 149, 678

Pemphigus 

(2020): Marion M+, Dermatol Ther Jun, Online ahead of print (1 case / male)Geriatric

(2018): Sood A+, Indian Dermatol Online J 9(5), 331-333 (1 case / female)

Pemphigus foliaceus 

(2018): Chen WS+, Int J Dermatol 57(10), e93-e95 (1 case / male)

Peripheral edema (see also edema) <10%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2015): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%

(2015): Kekale M+, Patient Prefer Adherence 9, 173375%

(2014): Thota NK+, Indian J Cancer 51(1), 5

(2013): Kanda T+, Int J Clin Oncol 18(1), 3837%

Petechiae <10%

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

Photosensitivity <10%

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2003): Rousselot P+, Br J Haematol 120(6), 1091

Pigmentation 

(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]

(2018): Fu Y+, Thorac Cancer Mar, Epub ahead of print56%

(2017): Kok WL+, J Dermatolog Treat 28(8), 762

(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]

(2016): Dervis E+, Eur J Dermatol 26(2), 133

(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (5 cases)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55422%

(2014): Linga VG+, South Asian J Cancer 3(4), 20354%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 560%

(2013): Sibaud V+, Ann Dermatol Venereol (French) 140(4), 266 [REVIEW]

(2012): Resende RG+, J Craniomaxillofac Surg 40(5), e140

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2004): Arora B+, Ann Oncol 15(2), 358

Pityriasis rosea 

(2011): Cho AY+, Ann Dermatol 23(Suppl 3), S360

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Brazzelli V+, J Am Acad Dermatol 53(5 Suppl 1), S240

(2003): Pasmatzi E+, Acta Derm Venereol 83(5), 391

(2002): Konstantopoulos K+, Dermatology 205(2), 172

Pityriasis rubra pilaris 

(2013): Plana A+, Clin Exp Dermatol 38(5), 520

Pruritus (itching) 6–10%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2013): Ensslin CJ+, J Am Acad Dermatol 69(5), 708 [REVIEW]10%

(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (22 cases)

Pseudolymphoma 

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Jardin F+, Lancet Oncol 6(9), 728

(2003): Clark SH+, J Cutan Pathol 30(4), 279

Psoriasis 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655

(2005): Shimizu K+, Rinsho Ketsueki 46(10), 1152

Purpura 

(2014): Anzalone CL+, Dermatol Online J 20(1), Epub [REVIEW] (periorbital)

Pyoderma gangrenosum 

(2013): Pinato DJ+, J Postgrad Med 59(3), 244

Rash 32–39%

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi (Chinese) 57(2), 1133%Pediatric

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16040%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]40%

(2016): Dervis E+, Eur J Dermatol 26(2), 133

(2016): Gomez-Almaguer D+, Hematology 21(7), 411 (4 cases) (with nilotinib)

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Lipton JH+, Lancet Oncol 17(5), 6121% (grade 3 or 4)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55411%

(2015): Kekale M+, Patient Prefer Adherence 9, 173332%

(2014): Linga VG+, South Asian J Cancer 3(4), 20315%Pediatric

(2013): Kanda T+, Int J Clin Oncol 18(1), 3837%

(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 438%

(2012): Kantarjian HM+, Blood 119(5), 1123

(2012): Radich JP+, Blood 120(19), 389828%

(2011): Khanna D+, Arthritis Rheum 63(11), 3540 (generalized)

(2009): Basso FG+, Support Care Cancer 17(4), 465

(2009): Cortes JE+, J Clin Oncol 27(28), 4754

(2005): Breccia M+, Eur J Haematol 74(2), 121

(2005): Modi S+, Breast Cancer Res Treat 90(2), 15725%

(2005): Severino G+, Ann Pharmacother 39(1), 162

(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]

(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (36 cases)

(2003): Verweij J+, Eur J Cancer 39(14), 200669%

(2001): van Oosterom+, Lancet 358(9291), 1421

Rosacea 

(2011): Demirci U+, J Oncol Pharm Pract 17(3), 285

Skin toxicity / toxicity 

(2017): Ransohoff JD+, Clin Lymphoma Myeloma Leuk 17(12), 834 [REVIEW]

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]30–44%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2016): Desar IM+, Anticancer Drugs 27(6), 576

(2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]

(2013): Brazzelli V+, J Eur Acad Dermatol Venereol 27(12), 1471 [REVIEW]

(2013): Trabelsi S+, Ann Biol Clin (Paris) (French) 71(2), 203

(2009): Mauro MJ+, Best Pract Res Clin Haematol 22(3), 409 [REVIEW]

(2003): Ugurel S+, Br J Cancer 88(8), 1157

Squamous cell carcinoma 

(2016): Inayat F+, Anticancer Res 36(11), 6201

(2003): Baskaynak G+, Eur J Haematol 70(4), 231

Stevens-Johnson syndrome 

(2018): Fakoya AOJ+, Open Access Maced J Med Sci 6(4), 730 [REVIEW]

(2018): Ng CY+, J Immunol Res Jan, Epub [REVIEW]

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2014): Bois E+, J Oncol Pharm Pract 20(6), 476

(2013): Jha P+, BMJ Case Rep 2013

(2012): Lamchahab M+, Ann Dermatol Venereol 139(12), 828

(2009): Hsieh HJ+, Chemotherapy 55(4), 197Geriatric (with allopurinol)

(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2005): Pavithran K+, Indian J Dermatol Venereol Leprol 71(4), 288 [REVIEW]

(2005): Severino G+, Ann Pharmacother 39(1), 162 (with lansoprazole)

(2002): Hsiao LT+, Br J Haematol 117(3), 620

(2002): Vidal D+, Br J Haematol 119(1), 274

Telangiectasia 

(2016): Turhan AG, Leuk Lymphoma 57(11), 2731

Toxic epidermal necrolysis (Lyell's syndrome) 

(2018): Ng CY+, J Immunol Res Jan, Epub [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

Urticaria / hives 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216

Vasculitis (angiitis) / cutaneous vasculitis (angiitis) 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

Xerosis <10%

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Dervis E+, Eur J Dermatol 26(2), 133

Alopecia / hair loss 10–15%

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

(2016): Dervis E+, Eur J Dermatol 26(2), 133

Follicular mucinosis 

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2004): Yanagi T+, Br J Dermatol 151(6), 1276

Hypotrichosis 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW]

Nail disorder 

(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)

Nail dystrophy 

(2017): Benabbes M+, Ann Pharm Fr 75(3), 172

(2006): Deguchi N+, Br J Dermatol 154(6), 1216

Nail pigmentation 

(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]

(2006): Prabhash K+, Indian J Dermatol Venereol Leprol 72(1), 63

Onychomadesis 

(2020): Saraswat N+, Indian J Dermatol 65(3), 193-19829%

Cheilitis 

(2016): Dervis E+, Eur J Dermatol 26(2), 133

Mucocutaneous eruption (includes fixed eruption) 

(2014): Grasso V+, G Ital Dermatol Venereol 149(3), 317 [REVIEW]

Mucositis 

(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases)Pediatric (with methotrexate)

(2014): Thota NK+, Indian J Cancer 51(1), 515%

Oral lichenoid eruption 

(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14

(2004): Ena P+, J Dermatol Treatment 15(4), 253

(2002): Lim DS+, Dermatology 205(2), 169

Oral pigmentation 

(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]

(2012): Resende RG+, J Craniomaxillofac Surg 40(5), e140

(2012): Yu YH+, Tex Dent J 129(8), 764

(2011): Mattsson U+, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(5), e12

Oral ulceration (see also aphthous stomatitis / aphthous ulcer / aphtha) 

(2014): Linga VG+, South Asian J Cancer 3(4), 2039%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 515%

(2009): Basso FG+, Support Care Cancer 17(4), 465

Oropharyngeal pain 

(2013): Kim KA+, Clin Ther 35(10), 1595 (mild / 1 case)

Xerostomia (dry mouth) 

(2015): Kekale M+, Patient Prefer Adherence 9, 173344%

Cardiac failure 

(2011): Toubert ME+, Thyroid 21(4), 451 (fatal)Fatal (with sorafenib)

Cardiotoxicity 

(2016): Chen ZI+, Mol Clin Oncol 4(5), 675 [REVIEW]

(2006): Kerkela R+, Nat Med 12(8), 908

Congestive heart failure 

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]<1%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Myocardial infarction 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Pericardial effusion 

(2021): Su PY+, J Infect Chemother Oct, Online ahead of print (1 case / male)

(2019): Terry C+, BMJ Case Rep 12(9), e229975 (1 case)Pediatric

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

Pulmonary edema / cardiogenic pulmonary edema 

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

QT prolongation 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2012): Radich JP+, Blood 120(19), 38981%

Anorexia 

(2014): Thota NK+, Indian J Cancer 51(1), 526%

(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 43

(2012): Radich JP+, Blood 120(19), 389810%

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

Anxiety 

(2015): Kekale M+, Patient Prefer Adherence 9, 173319%

Aphasia 

(2009): Janssen JJ+, Am J Hematol 84(10), 679

Cerebral hemorrhage 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Chills 11%

(package insert)

Confusion 

(2009): Janssen JJ+, Am J Hematol 84(10), 679

Depression 15%

(2015): Kekale M+, Patient Prefer Adherence 9, 173321%

(2003): Prescrire Int 12(68), 216

Fever (pyrexia) 13–41%

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 1136%Pediatric

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%

Headache 19–37%

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print5%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16037%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]37%

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2012): Radich JP+, Blood 120(19), 389819%

Hypoesthesia (numbness) <10%

(package insert)

Insomnia 10–19%

(package insert)

Memory loss/memory impaired 

(2015): Kekale M+, Patient Prefer Adherence 9, 173319%

Pain 

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11323%Pediatric

(2015): Kekale M+, Patient Prefer Adherence 9, 173319%

Paresthesias 

(2015): Kekale M+, Patient Prefer Adherence 9, 173328%

Sleep disturbances 

(2015): Kekale M+, Patient Prefer Adherence 9, 173324%

Somnolence (drowsiness) 

(2015): Kekale M+, Patient Prefer Adherence 9, 173318%

Subdural hemorrhage 

(2015): Frost AE+, J Heart Lung Transplant 34(11), 1366 (6 cases)

(2013): Hoeper MM+, Circulation 127(10), 1128

Tremor 

(2019): Obeidat K+, Case Rep Oncol 12(3), 913 (1 case)

(2015): Jang BH+, Korean J Gastroenterol 65(6), 366 (1 case)

(2011): Cameron S+, Case Rep Oncol 4(3), 505 (1 case)

Vertigo / dizziness 

(2013): Kim KA+, Clin Ther 35(10), 1595 (mild / 1 case)

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

Appetite decreased 

(2015): Kekale M+, Patient Prefer Adherence 9, 173318%

Aspartate aminotransferase (AST) increased 

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

Growth retardation  

(2014): Linga VG+, South Asian J Cancer 3(4), 20329%Pediatric

Gynecomastia 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2011): Liu H+, BMC Gastroenterol 11, 116 (6 cases)

(2005): Kim H+, J Korean Med Sci 20(3), 512 (unilateral)

(2003): Gambacorti-Passerini C+, Lancet 361(9373), 1954

Hyperlipasemia 

(2015): Blay JY+, Lancet Oncol 16(5), 5505% (grade 3 or 4)

Hypophosphatemia 

(2020): Ivanovic-Zuvic D+, Rev Med Chil (Spanish) 148(3), 404-408 (1 case / male)

(2019): Sakurada H+, Gan To Kagaku Ryoho (Japanese) 46(5), 891-894 (12 cases)

(2015): Blay JY+, Lancet Oncol 16(5), 5506% (grade 3 or 4)

(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34(2), 93

(2007): Osorio S+, Am J Hematol 82(5), 394-539%

(2006): Berman E+, N Engl J Med 354(19), 2006-13

Hypothyroidism 

(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]25%

(2012): Zygulska AL+, Endokrynol Pol 63(4), 302

Hypovitaminosis 

(2017): Choeyprasert W+, Pediatr Int 59(3), 286 (vitamin D)

Porphyria cutanea tarda 

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2004): Breccia M+, Leukemia 18(1), 182

(2003): Ho AY+, Br J Haematol 121(2), 375

Pseudoporphyria 

(2016): Batrani M+, Indian J Dermatol Venereol Leprol 82(6), 727

(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

(2014): Mahon C+, Pediatr Dermatol 31(5), 603 (2 cases)

(2010): Berghoff AT+, J Am Acad Dermatol 63(1), e14

(2009): Timmer-de Mik L+, Clin Exp Dermatol 34 (6), 705

Thyroid dysfunction 

(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]

Weight gain 5–32%

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55413%

(2014): Linga VG+, South Asian J Cancer 3(4), 20339%Pediatric

(2013): Matti BF+, Turk J Haematol 30(4), 38752%

Abdominal pain 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]37%

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2015): Blay JY+, Lancet Oncol 16(5), 5504% (grade 3 or 4)

(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases)Pediatric (with methotrexate)

Ascites 

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2015): Cortes J+, Am J Hematol 90(4), e66

Constipation 9–16%

(2014): Linga VG+, South Asian J Cancer 3(4), 2038%Pediatric

(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 432%

Diarrhea 25–59%

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print12% (3% grade 3/4)

(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print16%

(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16045%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]45–52%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]45%

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Paolino G+, Cutis 97(6), e12 (passim)

(2015): Kekale M+, Patient Prefer Adherence 9, 173350%

(2015): Klein Hesselink EN+, Eur J Endocrinol 172(5), R215 [REVIEW]7%

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94726%

(2014): Linga VG+, South Asian J Cancer 3(4), 2039%Pediatric

(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]

(2014): Thota NK+, Indian J Cancer 51(1), 540%

(2013): Matti BF+, Turk J Haematol 30(4), 38719%

(2012): Radich JP+, Blood 120(19), 389841%

(2011): Khanna D+, Arthritis Rheum 63(11), 3540

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)

Dyspepsia / functional dyspepsia / gastroparesis 

(2014): Linga VG+, South Asian J Cancer 3(4), 2038%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 513%

Gastric antral vascular ectasia (GAVE) 

(2016): Abu-Amna M+, Anticancer Res 36(11), 6151-6154 (1 case / female)

(2016): Narukawa K+, Intern Med 55(1), 69-72 (3 cases)

(2016): Oshima Y+, Int J Hematol 103(5), 596-8

(2015): Ong J+, Int J Hematol 102(5), 639-42 (3 cases)

(2014): Alshehry NF+, Clin Case Rep 2(3), 77-8 (1 case)

Gastrointestinal bleeding 

(2016): Banakh I+, Clin Case Rep 4(5), 486 [REVIEW]

(2015): Montagnac R+, Nephrol Ther (French) 11(6), 496

(2014): Saito M+, Rinsho Ketsueki (Japanese) 55(1), 130

Hepatitis 

(2015): Suzuki R+, J Pediatr Hematol Oncol 37(6), e368

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 6–12%

(2018): Shah JM+, Cureus 10(4) (passim)

(2017): Osorio S+, J Oncol Pharm Pract Jan, Epub ahead of print (with sertraline)

(2017): Shahbaz O+, Expert Opin Drug Metab Toxicol 13(9), 935 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]5% (grade 3 or 4)

(2016): Lipton JH+, Lancet Oncol 17(5), 6122% (grade 3 or 4)

(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)

(2016): Vincenzi B+, Expert Opin Drug Saf 15(9), 1219 [REVIEW]

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55410%

(2015): Egron A+, Target Oncol 10(2), 229 (2 cases)

(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases)Pediatric (with methotrexate)

(2014): Linga VG+, South Asian J Cancer 3(4), 2033%Pediatric

(2012): Seidel C+, BMC Cancer 12(1), 186

(2010): Bilgi N+, Ann Pharmacother 44(5), 926 (with ginseng)

(2010): Tonyali O+, Med Oncol 27(3), 768

(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]

(2007): Arai A+, Int J Hematol 86(3), 233

(2007): Kong JH+, Acta Haematol 118(4), 205

(2007): Ridruejo E+, World J Gastroenterol 13(48), 6608 (fatal)Fatal (with acetaminophen)

(2006): Cross TJ+, Am J Hematol 81(3), 189

(2006): Ikeda K+, Leuk Lymphoma 47(1), 155

Nausea 42–73%

(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print57% (1% grade 3/4)

(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print18%

(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11323%Pediatric

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16050%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]40–60%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]50%

(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Paolino G+, Cutis 97(6), e12 (passim)

(2015): Kekale M+, Patient Prefer Adherence 9, 173350%

(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases)Pediatric (with methotrexate)

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Thota NK+, Indian J Cancer 51(1), 540%

(2013): Kanda T+, Int J Clin Oncol 18(1), 3839%

(2013): Kim KA+, Clin Ther 35(10), 1595 (mild / 4 cases)

(2012): Radich JP+, Blood 120(19), 389851%

(2011): Khanna D+, Arthritis Rheum 63(11), 3540

(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)

Pancreatitis / acute pancreatitis 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Vomiting  23–58%

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 1136%Pediatric

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16023%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Paolino G+, Cutis 97(6), e12 (passim)

(2015): Kekale M+, Patient Prefer Adherence 9, 173322%

(2015): Klein Hesselink EN+, Eur J Endocrinol 172(5), R215 [REVIEW]7%

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94716%

(2014): Thota NK+, Indian J Cancer 51(1), 540%

(2013): Matti BF+, Turk J Haematol 30(4), 38719%

(2012): Kantarjian HM+, Blood 119(5), 1123

(2012): Radich JP+, Blood 120(19), 389820%

(2011): Khanna D+, Arthritis Rheum 63(11), 3540

Dysuria 

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

Sexual dysfunction 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Testicular hydrocele 

(2005): Kim H+, J Korean Med Sci 20(3), 512

Anemia 

(2020): Deng M+, Medicine (Baltimore) 99(7), e19150Pediatric

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print90% (29% grade 3/4)

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]4% (grade 3 or 4)

(2015): Blay JY+, Lancet Oncol 16(5), 5505% (grade 3 or 4)

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Linga VG+, South Asian J Cancer 3(4), 20365%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 560%

(2013): Kang YK+, Lancet Oncol 14(12), 117529% (grade 3 or worse)

(2013): Matti BF+, Turk J Haematol 30(4), 38713% (grade 2)

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)

Cytopenia 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 5547%

Eosinophilia 

(2017): McGrath K+, Ann Allergy Asthma Immunol 119(1), 85

Febrile neutropenia 

(2010): Hwang JE+, BMC Cancer 10, 438

(2007): Oki Y+, Cancer 109(5), 89932% (with decitabine)

Hematological adverse effect 

(2021): Eskazan AE+, Clin Lymphoma Myeloma Leuk Apr, Online ahead of printGeriatric (with underlying comorbidities )

Hemorrhage 

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16029%

Hemotoxicity 

(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11320%Pediatric

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2015): Cortes J+, Am J Hematol 90(4), e66

(2013): Latagliata R+, Drugs Aging 30(8), 62919% (grade 3–4)

(2012): Radich JP+, Blood 120(19), 3898

Hypofibrinogenemia 

(2019): Nair RR+, Blood Coagul Fibrinolysis 30(5), 246-248 (1 case / male)

(2018): Sciumè M+, Leuk Lymphoma 59(10), 2516-2517

Hypogammaglobulinemia 

(2020): Totadri S+, Pediatr Hematol Oncol May, Epub ahead of print17%Pediatric

(2008): Santachiara R+, Haematologica 93(8), 125210%

(2003): Steegmann JL+, Haematologica 88(7), 76220–25% (patients previously treated with interferon alpha)

Leukocytopenia (leukopenia) 

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94722%

(2013): Kanda T+, Int J Clin Oncol 18(1), 3839%

(2013): Matti BF+, Turk J Haematol 30(4), 3878%

Myelosuppression / bone marrow suppression / myelotoxicity 

(2009): Cortes JE+, J Clin Oncol 27(28), 4754

(2007): Oki Y+, Cancer 109(5), 899 (with decitabine)

Neutropenia (neutrophils decreased) 

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print75% (24% grade 3/4)

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]7% (grade 3 or 4)

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]17% (grade 3 or 4)

(2016): Lipton JH+, Lancet Oncol 17(5), 6128% (grade 3 or 4)

(2016): Liu Y+, J Cancer Res Ther 12 (Supplement), 23 [REVIEW]

(2015): Brummendorf TH+, Br J Haematol 168(1), 69

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94730%

(2014): Linga VG+, South Asian J Cancer 3(4), 20328%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 540%

(2013): Kanda T+, Int J Clin Oncol 18(1), 3840%

(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 4327%

(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34 (2), 93

(2012): Cortes JE+, J Clin Oncol 30(28), 3486

(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]

Pure red cell aplasia 

(2010): Tanaka H+, Intern Med 49(12), 1195

Thrombocytopenia 

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print79% (38% grade 3/4)

(2016): Banakh I+, Clin Case Rep 4(5), 486 [REVIEW]

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]1% (grade 3)

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]9% (grade 3 or 4)

(2016): Gomez-Almaguer D+, Hematology 21(7), 411 (grade 4 / 1 case) (with nilotinib)

(2016): Lipton JH+, Lancet Oncol 17(5), 6127% (grade 3 or 4)

(2016): Liu Y+, J Cancer Res Ther 12 (Supplement), 23 [REVIEW]

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Linga VG+, South Asian J Cancer 3(4), 20317%Pediatric

(2014): Thota NK+, Indian J Cancer 51(1), 540%

(2013): Matti BF+, Turk J Haematol 30(4), 3874%

(2012): Radich JP+, Blood 120(19), 3898

Arthralgia 21–26%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16031%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2003): Prescrire Int 12(64), 49

Asthenia / fatigue 29–75%

(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]

(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print13%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16039%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]39%

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55440%

(2015): Kekale M+, Patient Prefer Adherence 9, 173322–50%

(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)

(2014): Linga VG+, South Asian J Cancer 3(4), 20315–23%Pediatric

(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]

(2014): Thota NK+, Indian J Cancer 51(1), 532%

(2013): Kang YK+, Lancet Oncol 14(12), 117510% (grade 3 or worse)

(2012): Radich JP+, Blood 120(19), 389854%

(2011): Khanna D+, Arthritis Rheum 63 (11), 3540

(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)

(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)

(2009): Cortes JE+, J Clin Oncol 27(28), 4754

(2005): Modi S+, Breast Cancer Res Treat 90(2), 15756%

(2003): Prescrire Int 12(68), 216

(2003): Verweij J+, Eur J Cancer 39(14), 200676%

(2002): Demetri GD+, N Engl J Med 347(7), 472

Ataxia 

(2009): Janssen JJ+, Am J Hematol 84(10), 679

Bone or joint pain 11–31%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16047%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]25–40%

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]31–47%

(2016): Dervis E+, Eur J Dermatol 26(2), 13312%

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94711%

(2014): Linga VG+, South Asian J Cancer 3(4), 20330%

(2014): Thota NK+, Indian J Cancer 51(1), 545%

(2013): Matti BF+, Turk J Haematol 30(4), 38736%

(2012): Cortes JE+, J Clin Oncol 30(28), 3486

(2012): Radich JP+, Blood 120(19), 389844%

(2003): Prescrire Int 12(64), 49<5%

Cramps 

(2019): Abou Dalle I+, Cancer Med Sep21%

Muscle spasm 

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16049%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]49%

(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)

(2016): Paolino G+, Cutis 97(6), e12 (passim)

(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)

(2016): Wasif K+, Cureus 8(10), e848 (passim)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55422%

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94722%

Myalgia/Myositis/Myopathy/Myotoxicity (see also Statin-induced necrotizing autoimmune myopathy) 16–62%

(2020): Phukan A+, Ann Hematol Oct, Online ahead of print43%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16024%

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2015): Kekale M+, Patient Prefer Adherence 9, 173388%

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%

(2012): Kantarjian HM+, Blood 119(5), 1123

(2009): Cortes JE+, J Clin Oncol 27(28), 4754

(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]

(2003): Prescrire Int 12(64), 49

(2002): Dagher R+, Clin Cancer Res 8(10), 3034

(2002): Tefferi A+, Blood 99(10), 3854

Osteonecrosis / avascular necrosis 

(2017): Viviano M+, J Korean Assoc Oral Maxillofac Surg 43(2), 120 (jaw)

(2014): Mancano MA, Hosp Pharm 49(2), 121 (tibia)

(2013): Yeh CN+, J Clin Oncol 31(16), e248 (tibia)

Osteopenia 

(2020): Deng M+, Medicine (Baltimore) 99(7), e1915043%Pediatric

Rhabdomyolysis 

(2010): Gordon JK+, Leuk Res 34 (6), 827

Conjunctival hemorrhage 

(2015): Cortes J+, Am J Hematol 90(4), e66

Corneal deposits 

(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]

Epiphora 25%

(2003): Fraunfelder FW+, J Ocul Pharmacol Ther 19(4), 37118%

Eyelid edema 

(2013): Kanda T+, Int J Clin Oncol 18(1), 3848%

(2004): Maalouf T+, J Fr Ophtalmol 27(1), 107

Macular edema 

(2005): Masood I+, J Cataract Refract Surg 31(12), 2427

Ocular adverse effect 

(2018): Cho AR+, J Korean Med Sci 33(7), e55

Optic edema 

(2017): Napolitano M+, Clin Case Rep 5(10), 1573

(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]

(2012): DeLuca C+, Optom Vis Sci 89(10), 16

Optic neuritis 

(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]

Periorbital edema 33%

(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2015): Kekale M+, Patient Prefer Adherence 9, 173375%

(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94714%

(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]70%

(2013): Verma R+, Indian J Pharmacol 45(6), 634

(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]

(2003): Fraunfelder FW+, J Ocul Pharmacol Ther 19(4), 37170%

(2003): Ramar K+, J Clin Oncol 21(1), 172

(2003): Verweij J+, Eur J Cancer 39(14), 200684%

(2002): Esmaeli B+, Cancer 95(4), 881

Retinopathy 

(2016): Bourgeois N+, Therapie (French) 71(4), 365

Hearing loss (hypoacusis) 

(2016): Wasif K+, Cureus 8(10), e848

(2012): Lin HW+, Otolaryngol Head Neck Surg 146(2), 335

(2009): Janssen JJ+, Am J Hematol 84(10), 679

(2008): Attili VS+, Leuk Res 32(6), 991 [REVIEW]

Ototoxicity 

(2016): Wasif K+, Cureus 8(10), e848

Fanconi syndrome 

(2016): Balak DM+, Clin Kidney J 9(1), 82 (passim)

(2008): Francois H+, Am J Kidney Dis 51(2), 298 (partial)

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

(2012): Mulder KE+, Invest New Drugs 30(6), 2400 (with cyclosporine)

Proteinuria 

(2011): Khanna D+, Arthritis Rheum 63(11), 3540

Renal failure 

(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases)Pediatric (with methotrexate)

(2010): Gafter-Gvili A+, Leuk Res 34(1), 123

Cough 11–27%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16020%

Dyspnea / shortness of breath 21%

(2015): Kekale M+, Patient Prefer Adherence 9, 173318%

Nasopharyngitis 10–31%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16031%

Pharyngitis 10–15%

(package insert)

Pleural effusion 

(2021): Su PY+, J Infect Chemother Oct, Online ahead of print (1 case / male)

(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]

(2012): Radich JP+, Blood 120(19), 38982%

(2011): Barber NA+, Target Oncol 6(4), 235 [REVIEW]

Pneumonitis 4–13%

(2017): Luo ZB+, Turk J Haematol 34(4), 362

(2010): Stakhina OV+, Ter Arkh 82 (2), 59 (interstitial)

Pulmonary toxicity 

(2015): Lee NR+, Korean J Intern Med 30(4), 550

(2011): Barber NA+, Target Oncol 6(4), 235 [REVIEW]

Rhinitis 17%

(package insert)

Upper respiratory tract infection 3–21%

(2016): Ault PS+, J Adv Pract Oncol 7(2), 16021%

Adverse effects 

(2016): Dervis E+, Eur J Dermatol 26(2), 13314% (cutaneous)

(2016): Lee WJ+, Int J Dermatol 55(5), e26837% (grade 3) (cutaneous)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55435% (gastrointestinal)

(2015): Belum VR+, Pediatr Blood Cancer 62(5), 798 (dermatologic)

(2015): Frost AE+, J Heart Lung Transplant 34(11), 136631%

(2015): Yuan A+, Oral Oncol 51(11), 1026 (oral)

(2014): Egron A+, Target Oncol 10(2), 229

(2014): Guerin A+, Curr Med Res Opin 30(11), 2317

(2014): Saavedra D+, Leuk Lymphoma 55(12), 281375% (non-branded formulation)

(2013): Hoeper MM+, Circulation 127(10), 112844%

(2013): Seferian A+, Eur Respir Rev 22(129), 217

(2013): Thielen N+, Ann Hematol 92(8), 1049 (high-dose / with cytarabine)

(2013): Verma R+, Indian J Pharmacol 45(6), 6345% (severe)

(2012): Sibaud V+, Ann Chir Plast Esthet 57(2), 106

Cancer 

(2009): Roszkiewicz F+, Pharmacology 84(1), 38 (fatal)Fatal (with dasatinib)

Death 

(2011): Toubert ME+, Thyroid 21(4), 451 (with sorafenib)

(2009): Roszkiewicz F+, Pharmacology 84(1), 38 (with dasatinib)

(2007): Ridruejo E+, World J Gastroenterol 13(48), 6608 (with acetaminophen)

Infection 

(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]

Side effects 

(2016): Caldemeyer L+, Curr Hematol Malig Rep 11(2), 71 [REVIEW]

(2011): Amitay-Laish I+, Dermatol Ther 24(4), 386 [REVIEW] (cutaneous)

Teratogenicity 

(2006): Ault P+, J Clin Oncol 24(7), 1204



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of imatinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Adverse reactions attributed to entire drug class Antineoplastic / anticancer agent

Hyperkeratosis 

(2020): Vastarella M+, Drug Saf Jan, Epub ahead of print [REVIEW]

Dysgeusia (taste perversion) 

(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (12 cases)

Peripheral neuropathy 

(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (13 cases)

(2021): Hung HW+, Int J Environ Res Public Health 18(11), 5677

(2021): Inoue M+, Sci Rep 11(1), 11324 [REVIEW]

(2021): Li T+, Neurol Sci 42(10), 4109-4121 [REVIEW]

(2021): Selvy M+, Support Care Cancer 29(7), 4033-4043

(2011): Balayssac D+, Expert Opin Drug Saf 10(3), 407-17 [REVIEW]

Corneal neuropathic changes 

(2021): Chiang JCB+, Ocul Surf 21, 221-237 [REVIEW]

Adverse effects 

(2021): Kawasumi K+, Mol Clin Oncol 14(1), 12

Tooth disorder 

(2005): Tredwin CJ+, J Dent Res 84(7), 596-602 [REVIEW]Pediatric

Toothache (odontalgia) 

(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (6 cases)

(2010): Zadik Y+, J Endod 36(9), 1588-92

Adverse reactions attributed to entire drug class Biologic

Psoriasis 

(2020): Afach S+, Br J Dermatol May, Online ahead of print [REVIEW]

(2020): Montolio Chiva L+, Reumatol Clin Mar, Epub ahead of print [REVIEW]

Infusion-related reactions 

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60034%Pediatric

Adverse effects 

(2020): Iannone LF+, PLoS One 15(11), eCollection

(2020): Roberti R+, Curr Med Res Opin Jun, Online ahead of print

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60035%Pediatric

Infection 

(2020): Klein A+, ACR Open Rheumatol 2(1), 373%

Adverse reactions attributed to entire drug class Tyrosine kinase inhibitor

Edema / fluid retention (see also peripheral edema) 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92944%

Exanthems 

(2018): Sanmartin O, Curr Probl Dermatol 53, 93

Pigmentation 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%

Rash 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92914%

Skin toxicity / toxicity 

(2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]

Nail disorder 

(2014): Prescrire Int 23(151), 180

Hypertension 

(2020): Gadd M+, Cancer Rep (Hoboken) Aug, e1275

(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]

Thyroiditis 

(2017): Rizzo LFL+, Medicina (B Aires) 77(5), 394

Weight gain 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%

Gastrointestinal disorder / discomfort 

(2019): Clapes V+, Pharmaceut Med 33(1), 2117%

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92932%

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 

(2019): Carretero-Gonzalez A+, Medicine (Baltimore) 98(47), e18098 (3 cases) (previous treatment with immune checkpoint inhibitors also implicated)

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%

(2015): Karczmarek-Borowska B+, Contemp Oncol (Pozn) 19(2), 87 [REVIEW]

Cytopenia 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 9298%

Asthenia / fatigue 

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92938%

(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]

Muscle spasm 

(2016): Yamada M+, Rinsho Ketsueki 57(4), 489

(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%

Respiratory disorder 

(2019): Clapes V+, Pharmaceut Med 33(1), 2112%

Page last updated 10/16/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top